Although this indicates that COL6A1 expression might be a diagnostic marker for tumor progression, as its increased expression is a hallmark of high-grade gliomas, further studies pointed at COL6A1 as a prognostic marker, because it is also associated with poor clinical outcome in grade IV glioblastoma multiforme (Turtoi et al., 2014). This evidence concerns the gene COL6A1 and central nervous system cancer.